"近年来，线下少有人气这么旺的大会了" "一对一沟通，品牌与渠道现场对接需求，美妆链定位精准" "做线下渠道就找美妆链"…… 12月3日-4日，以"新人类，新渠道，新增长点"为主题，BeautyLink美妆链"2025线下趋势Link大会"在杭州落幕。在3日举行的2025Beauty Link年度颁奖盛 典上，近千人的会场热闹非凡、交流活跃，参会者的赞叹声此起彼伏。 除颁奖典礼之外，同期举行的美妆链展会吸引了超500+品牌参与，并特别设置30+品牌线下首发专区。此外，本次大会还通过主论坛演讲、圆桌对话等形 式，邀请了行业协会负责人、知名品牌创始人、渠道操盘手及零售专家等嘉宾，围绕2025年线下渠道的新趋势、新策略、新机遇展开了深入探讨。 作为今年行业唯一深度聚焦线下市场的会议，美妆链本次大会通过精准的供需对接与高密度干货分享，不仅为品牌方与渠道商提供了切实可行的"减压处 方"，也为美妆实体零售探索出一条"精耕细作、高效转化"的线下增长新通路。 传统渠道的固有优势正在被削弱，这是毋庸置疑的事实。 青眼情报数据显示：今年1-10月CS渠道销售额同比仅增长0.39%，而国家统计局同期化妆品零售额增幅为4.6%。这当 ...

Summary of Guizhou Sanli Conference Call Company Overview - Guizhou Sanli primarily operates in the pharmaceutical industry, focusing on both hospital and over-the-counter (OTC) sales channels. The sales distribution is approximately 60%-70% from hospital channels and 30%-40% from OTC channels [2][4]. Key Points and Arguments - **Sales Channels**: The OTC channel is currently under pressure from retail pharmacies, which may limit short-term revenue growth. However, it holds significant long-term potential as a growth driver [2][3]. - **Acquisitions**: The company has expanded its product matrix through acquisitions of subsidiaries such as Dechangxiang, Haosite, Hanfang Pharmaceutical, and Wudi Pharmaceutical. This strategy enhances market competitiveness and covers various therapeutic areas including gynecology and orthopedic conditions [2][5][10]. - **Core Product Performance**: The core product, Kaihoujian, is crucial for revenue, with significant contributions from both children’s and adult formulations. The company aims to expand its presence in the OTC market while also pushing for inclusion in the essential drug list to boost hospital sales [4][7][8]. - **Financial Performance of Subsidiaries**: - Hanfang Pharmaceutical generates approximately 300-400 million yuan in revenue with a net profit of 40-60 million yuan. - Dechangxiang has around 100 million yuan in revenue and a net profit of about 15 million yuan. - Wudi Pharmaceutical focuses on orthopedic products, with revenue between 20-30 million yuan and a net profit of 3-5 million yuan [2][9][10]. Future Growth Drivers - The future growth of Kaihoujian is expected to come from: - Expanding the children’s formulation in the OTC market. - Enhancing the adult formulation's coverage across all sales channels. - Successful inclusion in the essential drug list, which would significantly increase hospital market penetration [7][8]. Key Factors for Future Development - The ability of Kaihoujian to be included in the essential drug list is critical for increasing market share. - The development of the OTC channel, including coverage in chain pharmacies and grassroots medical institutions, is essential. - Effective integration of newly acquired subsidiaries to improve overall productivity and profitability is vital for long-term success [8][11]. Challenges - Guizhou Sanli faces significant challenges from pressure in the OTC retail sector, which is expected to limit short-term revenue and profit growth. The company must closely monitor the impact of essential drug list adjustments and the integration of acquired subsidiaries to achieve expected returns [3][11].